샘플 요청 목록

 카트 문의
시장보고서
상품코드
1565676

카포시육종 시장 : 제품 유형별, 치료별, 진단별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Kaposi Sarcoma Market, By Product Type, By Treatment, By Diagnostic, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 288 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

카포시육종 시장 규모는 2023년에 1억 4,030만 달러에 달하며, 2024-2032년 CAGR 4.90%로 확대

카포시육종 시장 - 시장 역학

HIV 관련 카포시육종의 혁신적 치료가 시장 성장을 지지

HIV 관련 카포시육종(KS)에 대한 혁신적인 치료법은 환자의 예후를 개선하고 표적 치료에 대한 수요를 증가시켜 시장 성장을 가속하고 있습니다. 항레트로바이러스 치료와 KS에 특화된 치료의 발전은 삶의 질과 생존율을 향상시켜 이 분야에 대한 투자와 개발을 촉진하고 있다고 2022년 미국 암 학회가 발표한 연구. 이 연구는 HIV 관련 카포시육종에 대한 새로운 치료법의 도입으로 이 질환의 연간 이환율이 크게 감소하고 있음을 밝혔습니다. 특히 HIV 양성 환자의 카포시육종 발병률은 2010-2022년까지 약 40% 감소했으며, 이는 항레트로바이러스 치료와 표적 치료의 발전으로 인한 것으로 분석되었습니다.

카포시육종 시장 - 주요 인사이트

리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 4.90%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

제품 유형별로는 유행성(AIDS 관련) 카포시육종이 22023년 가장 높은 시장 점유율을 차지했습니다.

치료 세분화를 기준으로 보면, 2023년에는 HAART(Highly Active Antiretroviral Therapy: 고활성 항레트로바이러스 요법)가 주요 유형으로 나타났습니다.

진단 세분화에 따르면 2023년에는 생검이 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출에서 선두를 차지했습니다.

카포시육종 시장 - 세분화 분석 :

세계 카포시육종 시장은 제품 유형, 치료, 진단, 최종사용자 및 지역을 기준으로 세분화됩니다.

시장은 제품 유형에 따라 유행성(AIDS 관련) 카포시육종, 고전적(지중해형) 카포시육종, 풍토성(아프리카형) 카포시육종, 이소성(이식 관련) 카포시육종 등 세 가지로 분류됩니다. 카포시육종 시장에서 가장 두드러진 부문은 유행성(AIDS 관련) 카포시육종입니다. 이 유형은 카포시육종 발병의 주요 위험 요인인 HIV/AIDS의 높은 확산으로 인해 가장 중요한 유형이 되었습니다. 전 세계 에이즈 유행이 계속되는 가운데, 이 유형의 카포시육종은 여전히 중요한 관심사이며, 표적 치료 및 연구 수요를 주도하고 있습니다. 다른 질병 유형은 중요하지만 유행성 질병 유형의 유병률과 영향력에는 미치지 못합니다.

시장은 치료법에 따라 고활성 항레트로바이러스 요법(HAART), 방사선 요법, 수술, 냉동 수술, 화학요법, 생물학적 요법 등 6가지 범주로 나뉩니다. 카포시육종 시장에서 가장 두드러진 치료 부문은 HAART(Highly Active Antiretroviral Therapy)다. HAART는 카포시육종의 주요 위험 요인인 HIV/AIDS 감염에 대처하는 데 중요한 역할을하며 HAART로 HIV를 효과적으로 관리합니다, 바이러스를 통제하고 관련 합병증의 유병률을 감소시킴으로써 카포시육종의 예후를 크게 개선할 수 있습니다. 방사선 치료, 수술, 화학요법 등 다른 치료법도 중요하지만, HAART는 에이즈 관련 카포시육종의 근본 원인을 관리하는 데 중요한 역할을 하므로 HAART가 지배적인 접근법이 되고 있습니다.

카포시육종 시장 - 지역적 인사이트

북미 카포시육종(KS) 치료 시장은 몇 가지 중요한 요인의 영향을 받고 있습니다. 주로 HIV/AIDS와 관련된 카포시육종(KS)의 유행은 시장 역학에 영향을 미치며, 미국과 캐나다에서 대부분의 사례가 발생합니다. 항레트로바이러스 요법(ART)의 발전으로 KS 치료 성적이 개선되면서 특정 KS 치료제에 대한 시장 수요가 감소하고 있습니다. 그러나 진행성 사례와 재발로 인해 효과적인 치료법에 대한 필요성은 계속되고 있습니다. 표적 치료제의 연구개발과 임상시험이 시장 성장에 기여하고 있습니다. 대형 제약회사와 연구기관의 존재는 새로운 치료법 개발을 촉진하고 있습니다. 규제 프레임워크, 의료 정책, 의료 서비스에 대한 접근성 또한 시장 환경 형성에 중요한 역할을 하고 있습니다. 전반적으로 시장은 틈새 시장이지만 지속적인 기술 혁신과 환자 결과 개선에 초점을 맞추었습니다.

카포시육종 시장 - 경쟁 구도:

카포시육종 시장을 주도하는 기업은 HIV/AIDS 치료 및 종양 치료에 깊이 관여하는 길리어드 사이언스, 브리스톨 마이어스 스퀴브, 머크, 화이자와 같은 주요 기업입니다. 이 외에도 노바티스 AG, 로슈 홀딩스 AG, 일라이 릴리 등 주목할 만한 기업이 암 연구를 통해 기여하고 있습니다. 시장 역학은 항바이러스 요법, 표적치료제, 면역요법에 중점을 두고 있으며, 연구개발에 많은 투자가 이루어지고 있습니다. 규제 이슈와 카포시육종의 희소성이 시장 성장에 영향을 미치고 있습니다. 맞춤형 치료와 병용요법에 기회가 있습니다. 현재 진행 중인 기술 혁신과 치료 전략의 발전으로 경쟁 구도가 형성되고 있습니다.

목차

제1장 카포시육종 시장 개요

  • 조사 범위
  • 시장 추정년

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 카포시육종의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 카포시육종 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 지도제작
  • 규제 구조 분석

제5장 카포시육종 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 카포시육종 시장 구도

  • 카포시육종 시장 점유율 분석, 2023년
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 카포시육종 시장 - 제품 유형별

  • 개요
    • 부문 점유율 분석
    • 유행성(에이즈 관련) 카포시육종
    • 고전적(지중해형) 카포시육종
    • 풍토병성(아프리카) 카포시육종
    • 의원성(이식 관련) 카포시육종

제8장 카포시육종 시장 - 치료별

  • 개요
    • 부문 점유율 분석
    • 고활성 항레트로바이러스 요법(HAART)
    • 방사선 치료
    • 수술
    • 냉동요법
    • 화학요법
    • 생물학적 요법

제9장 카포시육종 시장 - 진단별

  • 개요
    • 부문 점유율 분석
    • 기관지경 검사
    • 소화관 내시경검사
    • 생검
    • 기타

제10장 카포시육종 시장 - 최종사용자별

  • 개요
    • 부문 점유율 분석
    • 병원
    • 홈케어
    • 기타

제11장 카포시육종 시장 - 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 - 카포시육종 업계

  • 경쟁 대시보드
  • 기업 개요
    • Gilead Sciences
    • Bristol-Myers Squibb
    • Merck &Co.
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Celgene Corporation(now part of Bristol-Myers Squibb)
    • AbbVie Inc.
    • Johnson &Johnson
    • Regeneron Pharmaceuticals
    • Incyte Corporation
    • Sandoz(a Novartis division)
    • Alimera Sciences

제13장 애널리스트의 전방위 전망

KSA 24.10.22

REPORT HIGHLIGHT

Kaposi Sarcoma Market size was valued at USD 140.30 million in 2023, expanding at a CAGR of 4.90% from 2024 to 2032.

Kaposi sarcoma (KS) is a rare and often aggressive cancer that originates from the cells lining blood vessels and lymphatic vessels. It is characterized by the development of abnormal growths or tumors on the skin, in the mouth, or internal organs. KS is most commonly associated with human herpesvirus 8 (HHV-8) infection and is frequently seen in individuals with weakened immune systems, such as those with HIV/AIDS. The market for Kaposi sarcoma treatments includes pharmaceuticals, such as antiretroviral drugs and chemotherapy agents, as well as targeted therapies and immunotherapies. The market dynamics are influenced by factors such as disease prevalence, advancements in treatment, and the availability of innovative therapies.

Kaposi Sarcoma Market- Market Dynamics

Innovative treatments for HIV-related Kaposi Sarcoma boosting market growth.

Innovative treatments for HIV-related Kaposi Sarcoma (KS) are driving growth in the market by improving patient outcomes and increasing demand for targeted therapies. Advances in antiretroviral therapies and KS-specific treatments enhance the quality of life and survival rates, prompting greater investment and development in this sector. 2022 study published by the American Cancer Society. The study revealed that the introduction of novel therapies for HIV-related Kaposi Sarcoma has led to a significant decline in the annual incidence rate of the disease. Specifically, the incidence of Kaposi Sarcoma among HIV-positive individuals decreased by approximately 40% from 2010 to 2022, attributed largely to advancements in antiretroviral therapies and targeted treatments.

Kaposi Sarcoma Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2024-2032)

Based on product type segmentation, Epidemic (AIDS Associated) Kaposi Sarcoma was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, is Highly Active Antiretroviral Therapy (HAART) was the leading type in 2023

Based on Diagnostic segmentation, Biopsy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Kaposi Sarcoma Market- Segmentation Analysis:

The Global Kaposi Sarcoma Market is segmented on the basis of Product Type, Treatment, Diagnostic, End User, and Region.

The market is divided into three categories based on product type: Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Iatrogenic (Transplant-Related) Kaposi Sarcoma. The most prominent segment in the Kaposi Sarcoma market is the Epidemic (AIDS Associated) Kaposi Sarcoma. This form of the disease has become the most significant due to the high prevalence of HIV/AIDS, which is a major risk factor for developing Kaposi Sarcoma. With the ongoing global AIDS epidemic, this type of Kaposi Sarcoma remains a critical concern, driving the demand for targeted treatments and research. The other types, while important, do not match the prevalence and impact of the epidemic variant.

The market is divided into six categories based on Treatment: Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy. The most prominent treatment segment in the Kaposi Sarcoma market is Highly Active Antiretroviral Therapy (HAART). HAART is significant because it addresses the underlying HIV/AIDS infection, which is a major risk factor for Kaposi Sarcoma. Effective management of HIV through HAART can lead to significant improvements in Kaposi Sarcoma outcomes by controlling the virus and reducing the prevalence of related complications. While other treatments like Radiation Therapy, Surgery, and Chemotherapy are also important, HAART's role in managing the root cause of AIDS-associated Kaposi Sarcoma makes it the dominant approach.

Kaposi Sarcoma Market- Geographical Insights

The North American market for Kaposi's sarcoma (KS) treatment is influenced by several key factors. The prevalence of KS, primarily linked to HIV/AIDS, impacts market dynamics, with the majority of cases seen in the U.S. and Canada. Advances in antiretroviral therapy (ART) have improved KS outcomes, reducing the market demand for specific KS treatments. However, the need for effective therapies continues due to ongoing cases and relapses. Research and development in targeted therapies and clinical trials are contributing to market growth. The presence of major pharmaceutical companies and research institutions enhances the development of new treatments. Regulatory frameworks, healthcare policies, and access to healthcare services also play a crucial role in shaping the market landscape. Overall, while the market is niche, it is supported by continuous innovation and a focus on improving patient outcomes.

Kaposi Sarcoma Market- Competitive Landscape:

The Kaposi sarcoma market is driven by key players including Gilead Sciences, Bristol-Myers Squibb, Merck & Co., and Pfizer Inc., who are deeply involved in HIV/AIDS and oncology therapies. Other notable companies like Novartis AG, Roche Holding AG, and Eli Lilly contribute through their oncology research. Market dynamics include a focus on antiviral, targeted, and immunotherapies, with significant investments in R&D. Regulatory challenges and the rare nature of Kaposi sarcoma impact market growth. Opportunities lie in personalized and combination therapies. The competitive landscape is shaped by ongoing innovations and advancements in treatment strategies.

Recent Developments:

In July 2024, The USFDA approved ForDoz's injection, which contains doxorubicin hydrochloride in liposome form, for use in treating certain cancers. This formulation aims to improve the drug's delivery and reduce side effects compared to traditional doxorubicin..

In February 2023, Researchers at the University of North Carolina School of Medicine have discovered a protein that helps the Epstein-Barr virus (EBV) and the Kaposi sarcoma-associated herpesvirus (KSHV) cause disease and spread.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL KAPOSI SARCOMA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • Bristol-Myers Squibb
  • Merck & Co.
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Eli Lilly and Company
  • Amgen Inc.
  • Celgene Corporation (now part of Bristol-Myers Squibb)
  • AbbVie Inc.
  • Johnson & Johnson
  • Regeneron Pharmaceuticals
  • Incyte Corporation
  • Sandoz (a Novartis division)
  • Alimera Sciences

GLOBAL KAPOSI SARCOMA MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Epidemic (AIDS Associated) Kaposi Sarcoma
  • Classic (Mediterranean) Kaposi Sarcoma
  • Endemic (African) Kaposi Sarcoma
  • Iatrogenic (Transplant-Related) Kaposi Sarcoma

GLOBAL KAPOSI SARCOMA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Highly Active Antiretroviral Therapy (HAART)
  • Radiation Therapy
  • Surgery
  • Cryosurgery
  • Chemotherapy
  • Biological Therapy

GLOBAL KAPOSI SARCOMA MARKET, BY DIAGNOSTIC- MARKET ANALYSIS, 2019 - 2032

  • Bronchoscopy
  • Gastrointestinal Endoscopy
  • Biopsy
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Kaposi sarcoma Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Kaposi sarcoma Market Snippet by Product Type
    • 2.1.2. Kaposi sarcoma Market Snippet by Treatment
    • 2.1.3. Kaposi sarcoma Market Snippet by Diagnostic
    • 2.1.4. Kaposi sarcoma Market Snippet by End User
    • 2.1.5. Kaposi sarcoma Market Snippet by Country
    • 2.1.6. Kaposi sarcoma Market Snippet by Region
  • 2.2. Competitive Insights

3. Kaposi sarcoma Key Market Trends

  • 3.1. Kaposi sarcoma Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Kaposi sarcoma Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Kaposi sarcoma Market Opportunities
  • 3.4. Kaposi sarcoma Market Future Trends

4. Kaposi sarcoma Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Kaposi sarcoma Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Kaposi sarcoma Market Landscape

  • 6.1. Kaposi sarcoma Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Kaposi sarcoma Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Epidemic (AIDS Associated) Kaposi Sarcoma
    • 7.1.3. Classic (Mediterranean) Kaposi Sarcoma
    • 7.1.4. Endemic (African) Kaposi Sarcoma
    • 7.1.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

8. Kaposi sarcoma Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Highly Active Antiretroviral Therapy (HAART)
    • 8.1.3. Radiation Therapy
    • 8.1.4. Surgery
    • 8.1.5. Cryosurgery
    • 8.1.6. Chemotherapy
    • 8.1.7. Biological Therapy

9. Kaposi sarcoma Market - By Diagnostic

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnostic, 2023 & 2032 (%)
    • 9.1.2. Bronchoscopy
    • 9.1.3. Gastrointestinal Endoscopy
    • 9.1.4. Biopsy
    • 9.1.5. Others

10. Kaposi sarcoma Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Others

11. Kaposi sarcoma Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Kaposi sarcoma Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Kaposi sarcoma Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Kaposi sarcoma Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Kaposi sarcoma Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Kaposi sarcoma Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Kaposi sarcoma Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. Bristol-Myers Squibb
    • 12.2.3. Merck & Co.
    • 12.2.4. Pfizer Inc.
    • 12.2.5. Novartis AG
    • 12.2.6. Roche Holding AG
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Amgen Inc.
    • 12.2.9. Celgene Corporation (now part of Bristol-Myers Squibb)
    • 12.2.10. AbbVie Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Regeneron Pharmaceuticals
    • 12.2.13. Incyte Corporation
    • 12.2.14. Sandoz (a Novartis division)
    • 12.2.15. Alimera Sciences

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제